News Novo aims for GLP-1 sales growth in China Novo expects Victoza and semaglutide to gain momentum.
Views & Analysis Pharma 2022: big pharma will remain a constant Pharma 2022: big pharma to maintain its position, ready to pounce on any newcomer that shows promise.
News Novo highlights key 'hypo' data from Tresiba at EASD Novo hopes data will justify higher price compared with rival.
News AZ talks up Bydureon data, GLP-1 and glucagon combo AstraZeneca is hoping new data showing its Bydureon diabetes drug cuts overall death risk could stave off competition from Novo Nordisk's potential next generation GLP-1 drug.
News Teva appoints Lundbeck's Kare Schultz as CEO Unlike AZ's Soriot, Schultz "couldn't refuse" top job at Teva.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
